In our research, the co-expression of CD44 and CD133 markers, as the most frequently analyzed putative cancer stem cell markers, was found to range from 0.2% to 55.2% (median 1.7%) in cells of tested tumor tissue samples. This evidence concerns the gene PROM1 and neoplasm.